The drug supply crisis that has gripped Britain’s healthcare system in recent weeks is now hitting hospitals. New data released today shows difficulties obtaining some of the most commonly used medications, including aspirin, ramipril for high blood pressure, and co-codamol, a combination of paracetamol and codeine used for pain relief. The shortages raise fresh questions about how vulnerable drug supply chains have become to global disruptions—and what the implications could be for other countries, including Israel.
Aspirin, Painkillers, and Blood Pressure Medication
According to data published in The Guardian, many hospitals across England are struggling to obtain common drugs. Of 42 public health system bodies that responded to the survey, 26 reported difficulties obtaining aspirin, 13 reported shortages of the painkiller co-codamol, and seven out of 43 reported shortages of ramipril, a drug used to treat high blood pressure and heart disease. One hospital was even forced to pay a higher price to secure the drug’s supply. The report reveals that many of the surveyed bodies were not properly prepared to handle the shortages, and some didn’t even report the difficulties to NHS England.
Why Now?
Britain’s drug supply system, like many healthcare systems worldwide, relies on a complex international production chain. The UK Department of Health notes that drugs marketed in the country come from a global, regulated supply chain, and that shortages can result from manufacturing problems, raw material shortages, and distribution disruptions. British reports have also mentioned geopolitical tensions, trade disputes, and problems at manufacturing plants as factors weighing on supply. Still, the entire shortage cannot be attributed to any single cause.
Britain Is Already Restricting Exports of Some Drugs
The scale of concern over drug supply is evident in the steps the British government is taking. Aspirin and ramipril appear on the list of drugs that cannot be exported from Britain or hoarded for commercial purposes, aimed at protecting available stock for patients in the country. Co-codamol also appears on this list. Ramipril was added to the restricted list last August, while restrictions on aspirin and co-codamol were imposed in early 2026.
What About Israel?
Despite the reported shortages in England, there is currently no basis to conclude that they are causing parallel shortages in Israel or that these same drugs are about to disappear from shelves here.
Israel’s Health Ministry operates a dedicated database of notifications about marketing discontinuations and expected drug shortages, based on reports that pharmaceutical companies are required to submit to the Pharmaceutical Division. The database is updated regularly and consolidates data on temporary marketing discontinuations and expected supply resumptions. In other words, the mere fact that a drug is in short supply in England does not automatically indicate a shortage in Israel. This depends on manufacturers, suppliers, countries of origin, and existing inventory in each market. Nevertheless, the British crisis illustrates how sensitive the global drug supply chain can be to disruptions, especially when it comes to basic medications in daily use by millions of patients.
British Authorities: Working to Minimize Impact
The UK Department of Health and NHS England operate a national mechanism for dealing with shortages, including working with manufacturers and suppliers, finding alternatives, and distributing guidance to the healthcare system when there is a supply disruption. According to official data published in August, Britain routinely tracks manufacturer reports of existing or expected drug shortages. Authorities emphasize that a notice of supply disruption does not necessarily mean patients will actually be unable to receive the drug, since in some cases there is existing stock, alternatives, or additional suppliers. For Israel’s healthcare system, developments in England are primarily a reminder of the importance of early monitoring of essential drugs, maintaining alternatives, and early detection of disruptions that could cross borders.